Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | HMOX1 | P09601 | 3/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19390253 | 0.90 | CYP19A1 (0.71) | CYP19A1CYP11B1CYP11B2TBXAS1QPCT | |
| SCHEMBL10247237 | 0.88 | HMOX1 (0.72) | CYP19A1CYP11B1CYP11B2TBXAS1QPCT | |
| SCHEMBL570591 | 0.83 | CYP11B1 (0.66) | CYP19A1CYP11B1TBXAS1KMT2AHMOX1 | |
| SCHEMBL4316370 | 0.82 | CYP11B1 (0.69) | CYP19A1CYP11B1CYP11B2TBXAS1KMT2A | |
| SCHEMBL16719036 | 0.82 | CYP19A1 (0.81) | CYP19A1CYP11B1CYP11B2TBXAS1KMT2A | |
| SCHEMBL27460992 | 0.82 | TBXAS1 (0.60) | CYP19A1CYP11B1CYP11B2TBXAS1KMT2A | |
| SCHEMBL6986190 | 0.82 | HMOX1 (0.79) | CYP19A1CYP11B1CYP11B2TBXAS1KMT2A | |
| SCHEMBL10788342 | 0.82 | TBXAS1 (0.65) | CYP19A1TBXAS1KMT2AHMOX1 | |
| SCHEMBL11253750 | 0.82 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL171734 | 0.81 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2TBXAS1QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270079-A1 | Water Soluble Homogeneous Catalysts That Are Recoverable By Phase Selectivity And Host-Guest Interactions | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20090029964-A1 | Novel carbapenem compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029964-A1 | Novel carbapenem compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-0588858-B1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA NV (BE) | 2003-09-17 | — | — | EP | disclosed |
| US-5468743-A | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-11-21 | — | — | US | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029964-A1 | Novel carbapenem compound | MGAM2, OXA1L, RIOX2 | CYP19A1 1367/4885CYP11B1 2664/4885CYP11B2 1462/4885 |
| US-20190270079-A1 | Water Soluble Homogeneous Catalysts That Are Recoverable By Phase Selectivity And Host-Guest Interactions | NUDC, CCNC, CXCL12 | CYP19A1 1536/4885CYP11B1 1329/4885CYP11B2 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.